The 2022 Heart Failure Guidelines: Everything You Need to Know for Modern Management

The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" marks a definitive shift in cardiovascular medicine. By replacing the 2013 guidelines and 2017 updates, this new framework integrates contemporary evidence into a unified strategy for care. The mission is clear: to adopt a patient-centric approach that moves beyond reactive treatment toward the proactive prevention, diagnosis, and management of heart failure (HF). This era of management emphasizes that early intervention is as critical as advanced therapy in improving long-term survival and quality of life.

Defining the Stages: From "At Risk" to "Advanced"

The guidelines categorize heart failure as a progressive spectrum rather than a static condition. By refining the stages of HF, clinicians can identify and treat patients earlier—often before the onset of physical symptoms. This includes new terminology such as "Pre-HF" to signal the need for urgent preventative action.

Stage	New Terminology	Clinical Criteria
Stage A	At Risk for HF	Patients at risk but without current or previous symptoms, structural heart disease, or abnormal biomarkers. Includes those with hypertension, diabetes, obesity, or exposure to cardiotoxins.
Stage B	Pre-HF	Patients without symptoms or signs of HF but with evidence of structural heart disease, increased filling pressures, or elevated biomarkers (natriuretic peptides or persistently elevated cardiac troponin).
Stage C	Symptomatic HF	Patients with structural heart disease and current or previous symptoms of HF (e.g., shortness of breath, fatigue, or swelling).
Stage D	Advanced HF	Patients with marked symptoms that interfere with daily life and lead to recurrent hospitalizations despite optimized medical therapy.

Understanding the Trajectory of Stage C

Once a patient reaches Stage C, they are categorized based on their clinical trajectory. It is vital to understand that Stage C is a chronic diagnosis; even if symptoms vanish, the patient remains in Stage C to ensure they continue receiving life-saving therapy. The guidelines identify four distinct paths:

• New Onset/De Novo HF: A new diagnosis without a previous history.
• Resolution of Symptoms: Symptoms have cleared, but structural heart issues may persist.
• Persistent HF: Ongoing symptoms and limited functional capacity.
• Worsening HF: Declining functional capacity and increasing symptoms.

Notably, the guidelines introduce the term "HF in remission." This specifically refers to patients who achieve a full resolution of symptoms, signs, and previous structural or functional heart abnormalities.

The Ejection Fraction (EF) Spectrum: New Classifications

Left Ventricular Ejection Fraction (LVEF) measures the percentage of blood the heart pumps out with each beat. The 2022 guidelines use specific LVEF thresholds to guide treatment, but they now emphasize that for any LVEF above 40%, diagnosis requires objective evidence of increased filling pressures (the pressures within the heart chambers, measured through imaging or invasive testing).

• HFrEF (Reduced EF): LVEF ≤40%.
• HFmrEF (Mildly Reduced EF): LVEF 41%–49%. Diagnosis requires evidence of increased filling pressures.
• HFpEF (Preserved EF): LVEF ≥50%. Diagnosis requires evidence of increased filling pressures.
• HFimpEF (Improved EF): This replaces "recovered EF." It refers to patients who previously had HFrEF (≤40%) but now have a follow-up LVEF >40%. This distinction is critical: "improved" does not mean the heart is "cured," and medications must be maintained to prevent a decline.

The "Four Pillars" of Treatment: GDMT Updates

For patients with HFrEF, the standard of care is now defined by four classes of medication known as Guideline-Directed Medical Therapy (GDMT). These "four pillars" are the foundation of modern management:

1. SGLT2 Inhibitors (SGLT2i): A major breakthrough, SGLT2i now have a Class 1 (strong) recommendation for HFrEF regardless of diabetes status.
2. Renin-Angiotensin System Inhibition: Preferred use of ARNi (Angiotensin Receptor-Neprilysin Inhibitors); otherwise, ACE inhibitors or ARBs.
3. Beta Blockers
4. Mineralocorticoid Receptor Antagonists (MRAs)

While SGLT2i are a Class 1 recommendation for HFrEF, they are also the leading recommendation (Class 2a) for patients with HFmrEF and HFpEF. This represents a significant shift, as other drugs (like ACEi, ARNi, and MRAs) currently hold a weaker Class 2b recommendation for the mildly reduced (HFmrEF) population.

Prevention and Early Intervention (Stages A & B)

Stopping the progression of HF before it becomes symptomatic is a primary goal of the 2022 updates.

Primary Prevention Checklist (Stage A)

• Blood Pressure Targets: Maintain a goal of <130/80 mm Hg.
• SGLT2i Use: For patients with Type 2 Diabetes and established cardiovascular disease or high risk, SGLT2i should be used to prevent HF hospitalizations.
• Lifestyle: Regular physical activity, weight management, healthy dietary patterns (like the DASH or Mediterranean diets), and smoking cessation.

Halting Progression (Stage B)

To prevent "Pre-HF" from becoming symptomatic, the guidelines recommend:

• ACE Inhibitors/ARBs: For patients with LVEF ≤40% to prevent symptoms and reduce mortality.
• Statins: For patients with a history of heart attack or acute coronary syndrome.
• Beta Blockers: For patients with a recent heart attack and LVEF ≤40%.

Spotlight on Cardiac Amyloidosis

Amyloid heart disease, often underdiagnosed, now has specific evidence-based pathways for screening and treatment. The guidelines emphasize rapid and accurate detection to initiate specialized care.

• Screening Tools: Clinicians should use serum and urine monoclonal light chain screening, bone scintigraphy (99mTc-PYP), and genetic sequencing.
• Advanced Treatment: Management includes tetramer stabilizer therapy (tafamidis) and anticoagulation where clinically indicated.

When to Seek Advanced Care

Patients in Stage D (Advanced HF) require specialized expertise. The guidelines recommend early referral to a specialty heart failure team for patients who experience recurrent hospitalizations or marked symptoms that interfere with daily life despite optimized GDMT.

A specialty team provides a comprehensive assessment for advanced therapies, including:

• Mechanical Circulatory Support: Assessment for Left Ventricular Assist Devices (LVADs).
• Transplantation: Evaluation for cardiac transplant suitability.
• Integrated Palliative Care: Focusing on quality of life, shared decision-making, and the potential use of palliative inotropes.

Conclusion: Top Takeaways for the Reader

The 2022 guidelines transition heart failure care from a reactive model to a proactive, evidence-driven discipline. By focusing on early stages (A and B) and the "Four Pillars" of therapy, we can significantly alter the disease's course.

Action Items for Patients and Clinicians

1. Identify the "At Risk" and "Pre-HF" Stages: Use biomarkers like natriuretic peptides and cardiac troponin, along with LVEF, to catch disease before symptoms start.
2. Commit to the Four Pillars: For HFrEF, ensure all four medication classes are utilized and titrated to the highest tolerated doses.
3. Confirm the Diagnosis: For any LVEF over 40%, ensure there is objective evidence of increased filling pressures to confirm HFmrEF or HFpEF.
4. Maintain Therapy for Improved EF: If LVEF improves (HFimpEF), do not stop GDMT. Continued therapy is necessary to maintain cardiac function.
5. Engage in Shared Decision-Making: Use these guidelines as a roadmap to align medical interventions with individual patient values and lifestyle goals.

These updates represent our best opportunity to maximize survival and enhance the quality of life for all patients living with or at risk for heart failure.